April 11, 2024
GlaxoSmithKline and Nagasaki University launched this month what would be one the largest epidemiological studies in Japan on the disease burden of respiratory syncytial virus (RSV) infection, covering adults aged 50 and older. Since Japan has had limited epidemiological literature...read more